Phase II trial of Bevacizumab (Svastin) in locally advanced cervical cancer found 'promising'
Thursday, January 16, 2014 - 14:00
in Health & Medicine
Addition of Bevacizumab to the existing standard of care for advanced cervical cancer was found to be safe and showed promising overall results. The 2- and 3- year overall survival rates were 89.8 percent and 80.2 percent, respectively.